PL2234631T3 - Związki i metody stosowane w terapii choroby naczyniowej - Google Patents

Związki i metody stosowane w terapii choroby naczyniowej

Info

Publication number
PL2234631T3
PL2234631T3 PL08862538T PL08862538T PL2234631T3 PL 2234631 T3 PL2234631 T3 PL 2234631T3 PL 08862538 T PL08862538 T PL 08862538T PL 08862538 T PL08862538 T PL 08862538T PL 2234631 T3 PL2234631 T3 PL 2234631T3
Authority
PL
Poland
Prior art keywords
compounds
treatment
methods
vascular disease
vascular
Prior art date
Application number
PL08862538T
Other languages
English (en)
Inventor
Johan Frostegard
Knut Pettersson
Original Assignee
Athera Biotechnologies Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Athera Biotechnologies Ab filed Critical Athera Biotechnologies Ab
Publication of PL2234631T3 publication Critical patent/PL2234631T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL08862538T 2007-12-18 2008-12-18 Związki i metody stosowane w terapii choroby naczyniowej PL2234631T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1459407P 2007-12-18 2007-12-18
EP08862538A EP2234631B1 (en) 2007-12-18 2008-12-18 Compounds and methods for the treatment of vascular disease
PCT/GB2008/004195 WO2009077764A1 (en) 2007-12-18 2008-12-18 Compounds and methods for the treatment of vascular disease

Publications (1)

Publication Number Publication Date
PL2234631T3 true PL2234631T3 (pl) 2013-03-29

Family

ID=40419062

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08862538T PL2234631T3 (pl) 2007-12-18 2008-12-18 Związki i metody stosowane w terapii choroby naczyniowej

Country Status (16)

Country Link
US (3) US8809497B2 (pl)
EP (1) EP2234631B1 (pl)
JP (1) JP2011506590A (pl)
KR (1) KR20100105652A (pl)
CN (1) CN102223892A (pl)
AU (1) AU2008337284B2 (pl)
BR (1) BRPI0821272A2 (pl)
CA (1) CA2708956C (pl)
DK (1) DK2234631T3 (pl)
ES (1) ES2393163T3 (pl)
HR (1) HRP20120797T1 (pl)
MX (1) MX2010006719A (pl)
PL (1) PL2234631T3 (pl)
PT (1) PT2234631E (pl)
SI (1) SI2234631T1 (pl)
WO (1) WO2009077764A1 (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2733902T3 (es) 2008-02-22 2019-12-03 Annexin Pharmaceuticals Ab Compuestos y procedimientos para la prevención o tratamiento de reestenosis
EP2349321B1 (en) 2008-10-17 2020-04-22 London Health Sciences Centre Research Inc. Annexin and its use to treat inflammatory disorders
ES2607066T3 (es) 2011-04-05 2017-03-29 Annexin Pharmaceuticals Ab Procedimientos terapéuticos y profilácticos, usos y composiciones que comprenden anexina A5
ES2617494T3 (es) * 2012-05-31 2017-06-19 G. Pohl-Boskamp Gmbh & Co. Kg Inducción de arteriogénesis con un donador de óxido nítrico tal como nitroglicerina
GB2542391A (en) 2015-09-17 2017-03-22 Annexin Pharmaceuticals Ab Process of manufacture
US11357823B2 (en) * 2019-08-30 2022-06-14 Suzhou Yabao Pharmaceutical R&D Co., Ltd Method for treating cerebral stroke
CN111494608A (zh) * 2020-05-08 2020-08-07 北京大学第三医院（北京大学第三临床医学院） 预防或治疗子痫前期及相关病症的药物及其应用
US20240141001A1 (en) 2021-06-14 2024-05-02 Institut National de la Santé et de la Recherche Médicale Mutated annexin a5 polypeptides and uses thereof for therapeutic purposes
WO2025086968A1 (zh) * 2023-10-25 2025-05-01 上海萨美细胞技术有限公司 一种用于治疗肺纤维化的药物

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002258397A1 (en) 2001-02-15 2002-09-12 King Pharmaceuticals, Inc. Manufacture of thyroid hormone tablets having consistent active moiety amounts
US7645739B2 (en) * 2001-02-21 2010-01-12 Alavita Pharmaceuticals, Inc. Modified annexin compositions and methods of using same
US20050222030A1 (en) * 2001-02-21 2005-10-06 Anthony Allison Modified annexin proteins and methods for preventing thrombosis
US7635676B2 (en) * 2001-02-21 2009-12-22 Alavita Pharmaccuticals, Inc. Modified annexin proteins and methods for their use in organ transplantation
CA2479187A1 (en) * 2002-03-15 2003-09-25 Astral, Inc. Immunostimulatory double stranded rna and methods of inducing, enhancing or modulating the immune response
US20040022731A1 (en) * 2002-04-26 2004-02-05 Alexei Bogdanov In vivo imaging of apoptosis
CA2486362A1 (en) * 2002-06-06 2003-12-18 Tze Chein Wun Novel recombinant anticoagulant proteins
US20060029668A1 (en) * 2002-10-24 2006-02-09 Ron Eyal S Sustained release L-arginine formulations and methods of manufacture and use
WO2005018436A2 (en) * 2003-08-26 2005-03-03 The Trustees Of Boston University Methods for the diagnosis, prognosis and treatment of metabolic syndrome
CA2540202A1 (en) * 2003-09-29 2005-04-21 Enos Pharmaceuticals, Inc. Sustained release l-arginine formulations and methods of manufacture and use
EP1755642B1 (en) * 2004-04-15 2010-01-13 Athera Biotechnologies Ab Annexin v for preventing plaque rupture
WO2005107789A1 (en) * 2004-04-30 2005-11-17 The Board Of Trustees Of The Leland Stanford Junior University Use of delta pkc peptides for modulation of reactive oxigen species
US7511016B2 (en) * 2004-07-07 2009-03-31 Mosamedix B.V. Annexins, derivatives thereof, and annexin-cys variants, as well as therapeutic and diagnostic uses thereof
WO2006017578A2 (en) 2004-08-02 2006-02-16 The Board Of Trustees Of The Leland Stanford Junior University Peptide sequence for modulation of delta protein kinase c
TW200612896A (en) * 2004-09-21 2006-05-01 Sankyo Co Pharmaceutical compositions containing with HMG-CoA reductase inhibitor and glutathione
JP4949661B2 (ja) * 2004-09-21 2012-06-13 第一三共株式会社 ＨＭＧ−ＣｏＡリダクターゼ阻害剤とグルタチオンを含有する医薬組成物
US7393833B2 (en) * 2005-03-09 2008-07-01 The Board Of Regents Of The University Of Oklahoma Chimeric proteins with phosphatidylserine binding domains
DK1960790T3 (en) * 2005-12-12 2017-03-06 Mosamedix Bv ANNEXIN DERIVATIVES SUITABLE FOR PREGNANCY FOR TREATMENT AND DIAGNOSIS

Also Published As

Publication number Publication date
DK2234631T3 (da) 2013-01-07
US20160235811A1 (en) 2016-08-18
EP2234631A1 (en) 2010-10-06
KR20100105652A (ko) 2010-09-29
US20150010531A1 (en) 2015-01-08
PT2234631E (pt) 2012-11-20
JP2011506590A (ja) 2011-03-03
SI2234631T1 (sl) 2013-02-28
HRP20120797T1 (hr) 2012-12-31
CA2708956A1 (en) 2009-06-25
US20100291064A1 (en) 2010-11-18
AU2008337284A1 (en) 2009-06-25
CN102223892A (zh) 2011-10-19
ES2393163T3 (es) 2012-12-19
US9682122B2 (en) 2017-06-20
CA2708956C (en) 2018-07-17
WO2009077764A1 (en) 2009-06-25
MX2010006719A (es) 2010-09-28
BRPI0821272A2 (pt) 2015-06-16
EP2234631B1 (en) 2012-09-12
US9649355B2 (en) 2017-05-16
AU2008337284B2 (en) 2014-09-18
US8809497B2 (en) 2014-08-19

Similar Documents

Publication Publication Date Title
IL194076A0 (en) Imidazolothiazole compounds for the treatment of disease
SI2118074T1 (sl) Spojine za preprečevanje in zdravljenje kardiovaskularnih bolezni
PL2001466T3 (pl) Rapamycyna w małej dawce do leczenia chorób związanych z przepuszczalnością naczyń
IL198663A0 (en) Tissue treatment methods
EP2097012A4 (en) DEVICES AND METHOD FOR TREATING HEART FAILURE
EP2170311A4 (en) COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING AUTOIMMUNE DISEASES
ZA201000316B (en) Compounds and methods for treatment of sickle cell disease or complications associated therewith
IL216967B (en) The history of 17-hydroxy-17-pentafluoroethyl-astra-9,4 (10)-diene-11-aryl and their use for the treatment of diseases
SI2234631T1 (sl) Spojine in postopki za zdravljenje ĺ˝ilne bolezni
IL204728A0 (en) Methods and compounds for treating retinol-related diseases
EP2091480A4 (en) SYSTEM FOR THE TREATMENT OF HEART TISSUE
GB0909297D0 (en) Composition for the treatment of skin conditions
IL213703A0 (en) Compounds and methods for the treatment of pain and other diseases
GB0715790D0 (en) Drug combination for the treatment of sialorrhoea
IL192933A0 (en) Benzoisoindole derivatives for the treatment of pain
EP2164494A4 (en) Methods of Treatment
IL226363A0 (en) Compounds and methods for treating cancer
PL2307380T3 (pl) Pochodne N’-nitroksyalkilonikotynamidu do leczenia chorób układu sercowo-naczyniowego
GB0620695D0 (en) Composition and methods for the treatment of nurdegenerative disease
IL185900A0 (en) Compositions and methods for the diagnosis and treatment of tumor
IL208231A0 (en) Agent for preventing and/or treating vascular diseases
IL205339A0 (en) Compounds and methods for the treatment of cancer
GB0623740D0 (en) Treatment of disease
GB0618309D0 (en) Compositions and methods for the treatment of disease
ZA200706159B (en) Compositions and methods for the diagnosis and treatment of tumor